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New and emerging therapies might provide benefit in patients with pulmonary arterial hypertension. Their effi-
cacy and safety will be compared with existing combination therapies in randomized clinical trials. Appropriate
end points for these trials need to be identified: these will include exercise testing, the composite end point of
time to clinical worsening, and hemodynamic markers, including advanced imaging modalities and biomarkers.
Quality-of-life questionnaires are useful and important secondary end points; pulmonary arterial hypertension-
specific questionnaires are currently being developed. Advantages and disadvantages of various trial designs,
including placebo-controlled monotherapy or add-on trials, noninferiority studies, and withdrawal trials are also
discussed. (J Am Coll Cardiol 2009;54:S97–107) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.007i
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phen the 2nd World Health Organization (WHO) con-
erence on Pulmonary Hypertension met in Evian in 1998,
he only approved medical treatment for pulmonary arterial
ypertension (PAH) was intravenous epoprostenol. By the
ime of the 3rd World Symposium on PAH, which took
lace in Venice in 2003, new therapies had emerged that
xtended and improved the quality of our patients’ lives.
ince the Venice meeting, an increasing number of agents,
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hosphodiesterase-5 inhibitors, are providing more options
or treatment. With these new agents comes a new chal-
enge: to design clinical trials that will guide us in making
he best therapeutic choices on the basis of currently
vailable therapies and those that are still in development.
he views presented here are a summary from the Task
orce on End Points and Clinical Trial Design that met at
he 4th World Symposium on Pulmonary Hypertension,
eld in Dana Point, California, in 2008.
atient Populations in
andomized Clinical Trials of PAH
key question concerns the types of PAH patients that can
easonably be considered together in a single randomized
ontrolled trial (RCT). To date, most pivotal studies in
AH have grouped together several subcategories of pa-
ients. Because of the relative rarity of this disease (1–4),
his strategy has allowed investigators to maximize recruit-
ent. Nevertheless, it is clear that disparate PAH popula-
ions are not biologically identical and often not even
imilar. Subgroup analyses of these trials, moreover, have
een limited because of the small numbers of subjects, and
o studies to date have prespecified subgroup analyses. Such
ost-hoc subgroup analysis should be viewed as hypothesis-
enerating. Thus, we still have only rudimentary data in
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pathogenesis and natural history
of the disease and clinical re-
sponse to current PAH-targeted
therapies.
Although more than 50% of
the patients included in random-
ized trials of PAH have had id-
iopathic PAH, many trials have
included a significant number of
patients with other forms of
PAH, such as that associated
with connective tissue disease
and congenital heart disease. Al-
though regulatory agencies have
been approving drugs for the
global indication of PAH on the
basis of data from such trials
since 2001, a paucity of data in
PAH subpopulations makes it
difficult to extrapolate specific
therapeutic approaches targeted
to them. What we have learned
from these trials is that most
drugs for PAH, with the possible
exception of sildenafil, seem to
be more efficient in patients with
idiopathic PAH than in those
with nonidiopathic PAH and,
furthermore, that patients with
connective tissue disease consis-
ently demonstrate a lesser response to treatment (5–9). With
notable exceptions, the intravenous (IV) epoprostenol in
cleroderma study (10) and the BREATHE-5 (Bosentan
andomised trial of Endothelin Antagonist THErapy) trial in
atients with congenital heart disease (11), most studies in
ubpopulations have been uncontrolled, and long-term data in
hese groups are scarce. The following options can be consid-
red:
Group all PAH patients together. This strategy has the
advantage of facilitating patient recruitment, but the
patients might not be biologically similar, and etiology
might modify treatment effect.
Do separate studies in each PAH subgroup. However,
this approach is resource intensive, and the results of
studies done in selected populations might not be gen-
eralizable to a broader population.
Generalize in some cases, and do prototype studies in
designated subgroups.
ecommendations. The pivotal studies in PAH treatment
ave included mainly subgroups within Group I. These
atients share sufficient pathophysiologic and pathobiologic
imilarities that they might reasonably be grouped together
n future studies (9,12,13). Recognizing that some compro-
Abbreviations
and Acronyms
BNP  brain natriuretic
peptide
CMRI  cardiac magnetic
resonance imaging
CPET  cardiopulmonary
exercise test
CTEPH  chronic
thromboembolic pulmonary
hypertension
FDA  Food and Drug
Administration
LV  left ventricular
NT-proBNP  N-terminal
pro-brain natriuretic peptide
NYHA  New York Heart
Association
PAH  pulmonary arterial
hypertension
PH  pulmonary
hypertension
RCT  randomized
controlled trial
RV  right ventricular
6MW  6-min walk
TtCW  time to clinical
worsening
WHO  World Health
Organizationise is necessary, the U.S. Food and Drug Administration aFDA) has not required significant effects within each
roup I subgroup and is likely to continue to approve global
ndications on the basis of such trials.
Patients in Groups II through V (i.e., those with non-
AH pulmonary hypertension [PH]) should be studied in
ndividual subgroups. The BREATHE-5 trial, in patients
ith Eisenmenger syndrome, a Group I subgroup, showed
hat such subgroup study is feasible and can be productive,
espite logistical complications (11).
Patients with sickle cell disease, portopulmonary hyper-
ension, or chronic thromboembolic pulmonary hyperten-
ion (CTEPH), who were underrepresented in the pivotal
rials, represent unique challenges that compel separate
nvestigative approaches (14,15). Substantial numbers of
atients have sickle cell disease, although this is a hetero-
eneous group and might be difficult to study. As for
atients with portopulmonary hypertension, they have been
xcluded from all studies, with the exception of the
LPHABET (Arterial Pulmonary Hypertension and Bera-
rost European Trial) (16), because of concerns for hepatic
oxicity and the fact that the treatment algorithm incorpo-
ates consideration of liver transplantation early in the
isease. Nonoperable CTEPH patients present a large
ollective. Although CTEPH patients have rarely been
ncluded in studies (6), the recent BENEFiT (Bosentan
ffects in iNopErable Forms of chronIc Thromboembolic
ulmonary hypertension) trial, which enrolled 157 patients
ith CTEPH, demonstrated the feasibility of such a study
esign (17). However, there remains an urgent need for
vidence-based decision-making for the pharmacologic
reatment of these patients.
It is possible that enrolling such subpopulations into clinical
rials on the basis of a presumed pathogenesis might not be
roductive and that a lack of rigorous entry criteria could dilute
reatment effect or even, in some cases, be unsafe. Therefore we
eed to continue to expand our knowledge of PH in these
on-PAH groups and exercise restraint in enrolling these
atients in RCTs until we know more about their disease.
nd Points in RCTs of PAH
rimary and secondary end points. Primary end points in
AH trials, as in other RCTs, must meet 3 criteria; they
hould be: 1) clinically relevant; 2) sensitive to treatment
ffect; and 3) measurable and interpretable. Secondary end
oints complement the primary end points by providing a
ore global view of the benefit of the drug being tested and
y clarifying its risk-to-benefit ratio. Secondary end points
ay be of 2 types: 1) those that, like primary end points, are
linically relevant and may be taken into consideration for
rug indications; and 2) “feel-good” end points, which are
ot likely to lead to a new indication or a change in labeling
ut might provide reassurance about the primary end point
long with new information about the disease. Some sec-
ndary end points might be exploratory analyses (i.e.,
lthough they might demonstrate biologically plausible
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June 30, 2009:S97–107 End Points and Clinical Trial Design in PAHffects, they remain hypothesis-generating and will need to
e confirmed by additional studies).
xercise testing. Exercise capacity is one of the most
mportant prognostic indicators in PAH. Several exercise
rotocols have been used in PAH assessment protocols
Table 1) (5,6,16,18–24). Of these, the 6-min walk (6MW)
est has been accepted by regulatory agencies and is most
ommonly used as a primary end point in RCTs. The 6MW
est correlates fairly well with peak aerobic capacity (25). It
lso has prognostic significance in PAH (26), and it can be
erformed simply and inexpensively. However, within-
ubject variability has been seen in the 6MW test, with
epeat testing on the same day resulting in a 66-ft improve-
ent in a study of patients with chronic obstructive pulmo-
ary disease (27), an 18-m improvement on 2 successive
ays in post-myocardial infarction patients (28), and a 4.2%
hange in patients with interstitial lung disease after 1 week
29). In addition, the 6MW test might be less discerning in
atients who are less ill (30). Drug effects on the 6MW test
end to be slow to manifest and modest (10% to 15%) and
ight not provide an accurate reflection of how patients
eally feel. Therefore, regulatory authorities are open to
ssessments of exercise capacity beyond the 6MW test, and
hese have been and continue to be explored (31).
Cardiopulmonary exercise testing (CPET) measures
etabolic gas exchange at rest and during exercise. It
uantitates aerobic capacity and ventilatory inefficiency in
rder to determine the severity of PAH (32) and might
rovide more sensitive exercise assessment than the 6MW
est early in the course of the disease (33). It might also
rovide a more complete physiologic assessment of the
ulmonary vasculature (32). The CPET is expensive and
as proven to be technically challenging to perform and
nterpret in the setting of a multicenter RCT. Nevertheless,
ecause exercise capacity measured by CPET (peak oxygen
onsumption) is prognostic in PAH patients (34), it has
een used as a primary end point in 2 clinical trials (20,35).
n the STRIDE-1 (Sitaxsentan To Relieve Impaired Exer-
ise) multicenter trial, however, effects on peak oxygen
onsumption did not correlate with effects on the 6MW
est, probably due to technical difficulties in the CPET
rotocol and equipment (36).
Exercise duration at a constant work rate has been
roposed as an alternative to the 6MW test, because it
unctional Capacity Assessments
Table 1 Functional Capacity Assessments
Test Advan
6-min walk  Inexpensive
 Technically simple
 Useful in large groups of pa
Formal exercise testing (treadmill, cycle ergometry)  Most familiar
CPET  Provides objective measurem
and rate of exertion of ventila
 Reproducible
NYHA/WHO classification  Simple, large body of scientPET  cardiopulmonary exercise test; NYHA/WHO  New York Heart Association/World Health Organizight be more sensitive to changes in aerobic capacity (37).
readmill and cycle ergometry have been successfully used
s end points in PAH trials (38–40).
ecommendation. Although the 6MW test has been the
ost common primary end point in clinical trials and its use
as led to the approval of many agents by regulatory
uthorities, several questions remain, including: 1) What is
clinically relevant improvement in 6MW test? 2) How
hould variables that are known to affect the 6MW test,
uch as age and height, be factored into this end point? 3) Is
he 6MW test still a sensitive exercise test as we study
atients earlier in the course of the disease?
Regardless of the type of assessment, some evaluation of
hange in exercise capacity will continue to be an important
utcome measure in ongoing trials, if only as a secondary
nd point, and additional and more sensitive methodologies
hould be explored.
ime to clinical worsening. Recent studies in PAH have
een similar in design, with exercise capacity as a primary
nd point, and with a blinded phase ranging from 3 to 6
onths and, in 1 case (20), to 12 months. Because of the
ow event rate, mortality alone would not be an adequately
owered end point in this setting. Therefore, a composite
nd point, time to clinical worsening (TtCW), has been
eveloped and is generally included as a secondary end
oint.
Different definitions of TtCW have been used in different
tudies (5,20,22,24,35,41–44), making comparison difficult
Table 2). However, common components have been time-
rom-randomization to: 1) all-cause mortality; 2) hospital
tay for PAH; 3) need for interventional procedures (trans-
lantation or balloon atrial septostomy); and 4) clinical
rogression of PAH. Some definitions of TtCW have also
ncluded a combination of deterioration of 6MW test
istance from a baseline of 10% to 20%, an increase in New
ork Heart Association/World Health Organization
NYHA/WHO) functional class, symptoms of right heart
ailure, and/or escalation of medical treatment. In consid-
ring a single definition of TtCW, the following definitions
re possible:
Only all-cause mortality and hospital stays for PAH.
Despite the fact that thresholds for hospital stay might
differ according to geographic areas and health sys-
Disadvantages
 Subject to patient effort
 Unable to measure gas exchange, ventilatory efficiency
 Unable to measure gas exchange, ventilatory efficiency
f peak metabolism
d circulatory reserves
 Technically more difficult
rature  Subjectivetages
tients
ents o
tory an
ific liteation.
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End Points and Clinical Trial Design in PAH June 30, 2009:S97–107tems, hospital admission for PAH progression is
usually considered to be an objective measure of
deterioration (45).
Adding interventional procedures to death and hospital
stay. However, the availability of such procedures might
also vary from country to country, and in any case, they
are very rarely performed in the setting of RCTs.
Inclusion of an additional event, defined as progression of
PAH that does not require hospital stay. This category
might include progression of NYHA/WHO functional
class, symptoms of right heart failure, and the need for
additional therapies, as determined by the physician/
investigator.
Because TtCW should be used only in blinded trials,
isease progression might be a subjective and therefore a
eak end point. To address this, the physician/investigator
ould be required to provide “measurable” parameters for
upporting the definition of PAH progression or the deci-
ion to increase medical therapy.
As with all composite end points, the U.S. FDA has
xpressed concern about TtCW. Although they have ac-
epted it as a primary end point, they have suggested that it
ould be more useful if it were possible to assign a numerical
alue to each component, on the basis of community input.
hey have also suggested that total events is a broader, more
nclusive, and therefore stronger end point than time to first
vent.
ecommendations. We recommend that a uniform defi-
ition of TtCW be used in future pivotal (phase III) RCTs
n PAH. In the definition of TtCW, hard events would
nclude:
All-cause mortality
Nonelective hospital stay for PAH (with predefined
criteria, usually for initiation of intravenous prostanoids,
lung transplantation, or septostomy)
Disease progression defined as a reduction from baseline
in the 6MW test by 15%, confirmed by 2 studies done
within 2 weeks plus worsening functional class (except
for patients already in functional class IV)
efinition of Time to CW in Different Trials
Table 2 Definition of Time to CW in Different Trials
Component
BREATHE-1
& 351 (5,41)
EARLY
(42)
STR
(
Death ✓ ✓
Hospital stay ✓ ✓
Lung transplantation ✓
Atrial septostomy ✓
Symptomatic progression (NYHA/WHO FC) ✓ ✓
Lack of improvement or worsening PAH
(6-min walk)
✓ ✓
Need for additional PAH therapy ✓
p value 0.05 0.05 NW  clinical worsening; NYHA/WHO FC  New York Heart Association/World Health Organization functWe strongly suggest that, in all cases where TtCW is
sed as a primary end point in an RCT, some adjudication
f events should be mandatory.
There might not be sufficient numbers of patients in
hase IIb trials to use the TtCW end point. In these kinds
f trials, some type of exercise assessment should be used,
long with secondary confirmatory end points, to include
emodynamic data for new therapies. In phase III or pivotal
rials, however, we recommend TtCW as a primary end
oint, with assessment of exercise ability as a secondary end
oint. Trials with TtCW as a primary end point will likely
eed to be of longer duration than typical 12- to 16-week
rials that have used 6MW test as a primary end point. This
trategy would be acceptable to regulatory authorities.
uality-of-life assessments. A variety of instruments have
een developed to measure outcomes in PAH. Dyspnea is the
ost frequent complaint for which persons with PAH seek
edical attention, and numerous instruments exist to evaluate
yspnea during exercise and activities of daily living (46–52).
he Borg score (53), developed in 1982, has been shown to be
esponsive to interventions aimed at reducing dyspnea as well
s to therapeutic intervention in most PAH RCTs.
Global and health-related quality-of-life measurements are
lso used to evaluate patient perceptions of treatment effect.
hose that have been used with PAH patients include the St.
eorge’s Respiratory Questionnaire (54), the Minnesota Liv-
ng with Heart Failure questionnaire (55), the Chronic Heart
ailure Questionnaire (52), and a general-health questionnaire,
he Medical Outcomes Study Short Form-36 (56). In general,
ongestive heart failure-specific instruments have performed
etter than general health instruments in PAH patients. Two
roups have now started to develop a quality-of-life instrument
pecific to PH (including collagen vascular disease) that will
ddress concerns that have not been addressed in nondisease-
pecific instruments (57,58).
Regulatory agencies respond differently to these kinds of
nstruments. The European Medicines Agency might re-
ard them more favorably than the FDA, although both
rganizations regard them with caution. The FDA has
xpressed concerns that this end point is too amorphous and
eeds validation, particularly if it is not consistent with the
STRIDE-2
(22)
ARIES-1
(43)
ARIES-2
(43)
SUPER-1
(21)
STEP
(23)
PACES
(44)
✓ ✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ ✓
✓ ✓ ✓
✓ ✓ ✓
✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ ✓ ✓
NS NS 0.05 NS 0.05 0.005IDE-1
35)
✓
✓
✓
✓
Sional class; PAH  pulmonary arterial hypertension.
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June 30, 2009:S97–107 End Points and Clinical Trial Design in PAHrimary end point. The FDA is also concerned that cultural
ifferences, different types of assessments, and patient in-
erpretation might affect the outcome. To date, only 5
CTs in PAH have used health-related quality-of-life
nstruments.
ecommendations. Some evaluation of quality of life is
mportant. There is a need to develop and validate in
ulticultural fashion a disease-specific questionnaire that
ill be acceptable to both the FDA and the European
edicines Agency as a secondary end point in future trials.
maging and hemodynamic assessment. Hemodynamic
ata are not currently accepted as an end point for regulatory
uthorities. Nonetheless, these data provide valuable infor-
ation, because the functional capacity of the right ventricle
s a major prognostic determinant in PH, and death from
H usually results from right ventricular (RV) failure
59–62). Therefore, techniques that image RV morpho-
ogic and functional change in the face of increasing outflow
bstruction can greatly advance our understanding of the
isease. Such techniques include echocardiography, com-
uted tomography, radionuclide ventriculography, and car-
iac magnetic resonance imaging (CMRI).
ONINVASIVE. Echocardiography is routinely used for assess-
ng RV size and function and severity of PH. In 1 RCT (63),
dvanced PAH therapy improved many echocardiographic
ariables, including left ventricular (LV) area, systolic eccen-
ricity index, RV/LV diastolic areas ratio, pericardial effusion
core, RV ejection time, Doppler RV index, LV stroke volume
nd cardiac output, and parameters of LV filling. Improve-
ents in exercise capacity were also related to echocardio-
raphic changes. Thus, this technique is sufficiently sensitive to
linical changes to be used as a reinforcing end point. However,
tandardization of echocardiographic measurements, some of
hich can be highly technical, would be necessary to consider
his as an end point in clinical trials. Two indexes that might be
onsidered include the Tei Index and tricuspid annular plane
ystolic excursion (64,65). Although there is substantial interest
n exercise stress echocardiography, particularly in early disease,
his study is difficult to perform and interpret. Similarly,
lthough 3-dimensional echocardiography might improve our
nderstanding of the pathophysiology of RV failure in PAH, it
as been minimally evaluated in PAH patients.
CMRI is a safe and reproducible technique that allows
oth morphologic and functional assessment of the right
entricle (66). CMRI findings in PAH include RV dilation,
V hypertrophy, interventricular septal flattening or para-
oxical motion, and change in RV chamber morphology
rom a normal crescent shape to a more concentric form.
troke volume, cardiac output, and distensibility of pulmo-
ary arteries can also be assessed (67–69). CMRI imaging
as not been validated to measure pulmonary vascular
esistance, but good correlation between right heart cathe-
erization and CMRI suggests that CMRI data could be
sed as a surrogate for right heart hemodynamic status.
reliminary data suggest that the prognostic importance of tMRI measurements in PAH includes low stroke volume,
V dilation, and impaired LV filling (70). Furthermore,
ecause this technique is noninvasive, it can be used
epeatedly to determine disease progress or response to
herapy. Technical improvements in CMRI allow increas-
ngly rapid and robust data acquisition.
In the SERAPH (Sildenafil versus Endothelin Receptor
ntagonist for Pulmonary Hypertension) study in patients
ith idiopathic PAH, changes in RV mass measured by
MRI were a primary end point (71). CMRI is now
onsidered the gold standard for detailed study of the right
entricle and an established modality for the physiologic
ssessment of PAH patients in cross-sectional and longitu-
inal follow-up studies of therapy. It will likely be increas-
ngly used as the primary modality for anatomic and
unctional assessments that will enable more complete and
fficient evaluation of patients with PAH (72).
NVASIVE. Right heart catheterization, an invasive procedure,
rovides measurements of systemic blood pressure and satura-
ion, pulmonary arterial pressure and saturation, pulmonary
apillary wedge pressure, right atrial pressure, and cardiac
utput by thermodilution or Fick method if oxygen consump-
ion is measured. The hemodynamic definition of PAH is
ased on catheter measurements, which are accurate and
eproducible and, because the measurements are less noisy than
oninvasive imaging, require fewer patients to power clinical
rial end points. In addition, the data obtained have been
hown to be prognostic (59). However, the fact that these
easurements are made at rest rather than during exercise—
hen patients develop symptoms—limits its usefulness, as do
rocedural concerns, potentially including a need for dehydra-
ion after an overnight fast and sometimes the need for
edation. Some of the measurement techniques also have
articular limitations. Despite these limitations, routine right
eart catheterization provides a simple description of resting
emodynamic status that can be interpreted in the context of
he underlying disease process.
ecommendations. Imaging of the right ventricle, either by
chocardiography or CMRI, often provides clinically useful
nformation to the experienced clinician caring for an individ-
al patient. Similarly, invasive hemodynamic measures of RV
unction, particularly right atrial pressure and cardiac index,
rovide important clinical information and insight into disease
rogression. RV function has potent prognostic abilities, and it
s reasonable to consider indexes of RV function as secondary
nd points in pivotal clinical trials.
Hemodynamic measures provide a rational basis for deci-
ions on dose range and dosing intervals. At a minimum, these
hould be included in Phase II trials and should be considered
s exploratory secondary end points that advance our under-
tanding of PAH. They will very likely not be primary end
oints for registration in the foreseeable future.
iomarkers. Echocardiography, CMRI, or right-heart
atheterization provides accurate assessment of RV func-
ion, but right heart catheterization is invasive, and all these
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End Points and Clinical Trial Design in PAH June 30, 2009:S97–107odalities are costly. Therefore, various biomarkers have
een increasingly explored to assess cardiac function in
AH patients. These include the cardiac hormone brain
atriuretic peptide (BNP), a highly sensitive and specific
arker of LV failure; however, levels of brain and atrial
atriuretic peptides also seem to correlate with RV dysfunc-
ion (73–75). Many clinicians routinely order an assay for
NP or the inactive N-terminal-pro-fragment, NT-
roBNP, in the setting of PAH or congestive heart failure.
easurement of NT-proBNP is preferred over BNP, be-
ause it is more stable both in vivo and in vitro than the
ctive BNP molecule (76). Levels of NT-proBNP of ap-
roximately 1,400 to 1,700 ng/l1 seem to suggest a poor
rognosis (74,77). The NT-proBNP is now commonly used
n congestive heart failure and PAH (78). The NT-proBNP
evels also correlate with survival (74,77,79). Therefore, it
ight be reasonable to include NT-proBNP as a secondary
nd point in RCTs of PAH.
Acute RV strain might also be reflected in troponin
levation in patients with PH or CTEPH. Although the
ajority of stable patients with PAH do not have abnormal
roponin values, measurement of troponin levels could
mprove prognostication in more advanced patients. In spite
f similar hemodynamic status, patients with elevated tro-
onin levels in 1 study had higher heart rates, shorter 6MW
istances, lower mixed venous oxygen saturations, and
igher NT-proBNP levels; all were statistically significant
ompared with normal troponin values (80).
Serum uric acid levels are increased in obstructive pul-
onary disease (81), Eisenmenger syndrome (82), and other
ypoxemic settings (83). Serum uric acid levels increase in
roportion to the severity of idiopathic PAH, in which they
lso have a strong independent association with mortality
84). In functional class III patients with idiopathic PAH,
erum uric acid levels and diastolic blood pressure at peak
xercise independently predicted survival (p  0.005) (34).
erum uric acid levels are readily available; however, they are
omewhat nonspecific and might be affected by variables
uch as acute illness, drugs, tissue perfusion, decreased
lomerular filtration, and hypoxia. Nevertheless, in PAH, in
he absence of other causes of hypoxemia, uric acid levels
ight contribute to prognostication (84).
Other biomarkers that might potentially be useful in
atients with PH are D-dimer levels (85), endothelin-1
86), nitric oxide (87), prostaglandins (88), and cyclic
uanosine monophosphate (89). Although these show
romise, studies to date have been too small to be conclu-
ive, and practical considerations currently preclude their
outine use. Further studies are needed.
Although biomarker end points are important in clarify-
ng our understanding of PAH, it is unlikely that they will
e accepted by regulatory authorities as primary end points
n registration trials in the foreseeable future.
ummary of end point recommendations. Although we
elieve TtCW to be an important, clinically relevant pri-
ary end point in the modern era, we realize that Phase IIrials might not be large enough or of sufficient duration to
etect a meaningful difference in TtCW. For Phase II trials,
e recommend the 6MW test as a primary end point and
ncourage the inclusion of hemodynamic status as a second-
ry end point. For Phase III trials, we recommend TtCW as
he primary end point. A number of the secondary end
oints discussed in the preceding text might also be studied
n a Phase III trial. We suggest choosing a few but caution
gainst including too many secondary end points.
linical Trial Design
he RCT environment is becoming increasingly complex.
ix therapeutic agents have been approved for PAH in the
.S. and 7 in Europe, and many patients are already
eceiving some kind of approved therapy when they enroll in
CTs. Therefore, these trials increasingly involve add-on
herapy. Several designs have been proposed and/or used for
uture RCTs in the PAH populations:
Placebo-controlled monotherapy or add-on trials.
Placebo-controlled trials are still considered to be among
the strongest designs to evaluate new therapies. However,
because many patients are already receiving or have access
to some type of approved therapy, placebo-controlled
monotherapy trials might be considered unethical
(90,91). Nevertheless, because of the lack of evidence
regarding the efficacy of advanced therapies in non-
WHO Group I populations (e.g., patients with chronic
obstructive pulmonary disease or interstitial lung disease,
CTEPH, or PH due to diastolic dysfunction of the left
ventricle), it is reasonable to consider enrolling these
patients in placebo-controlled monotherapy RCTs.
Placebo-controlled RCTs might be reasonable as well
where the new treatment is added to standard therapy
and is compared with placebo added to standard therapy.
Noninferiority studies. Another approach might be to
perform head-to-head comparisons by conducting non-
inferiority studies. A noninferiority study aims to dem-
onstrate that the tested drug is not worse than the
comparator by more than a prespecified, small amount,
known as the noninferiority margin. The size of an
acceptable margin depends on the smallest clinically
significant difference, expected event rates, the estab-
lished efficacy advantage of the control over placebo, and
regulatory requirements. Noninferiority trials are statis-
tically based on a 1-sided comparison with an active
control in the positive direction. This trial design is
useful in cases where: 1) bioequivalence cannot be estab-
lished, as in modified-release products or topical presen-
tations; 2) new products have a potential safety advan-
tage, and therefore a risk-benefit assessment can be
made; 3) a direct comparison against the active compar-
ator is needed to assess risk-benefit; 4) no important loss
of efficacy compared with the active comparator would be
acceptable; and 5) a placebo arm is not possible, and an
active control trial is required to demonstrate the efficacy
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points can be used only along with primary end points
already investigated—in PAH, the 6MW test. They
must also replicate the setting of the pivotal study of the
comparator (i.e., inclusion and exclusion criteria, patient
population). One of the obstacles in conducting these
trials is the sample size, which would often need to be
500 patients, which limits the feasibility of such a
study, both in terms of cost and patient recruitment.
Thus, noninferiority studies have a number of inherent
weaknesses, and they have not yet been used in PAH
registration studies.
Withdrawal trials. The current standard of therapy for
PAH usually involves initial use of oral endothelin
antagonists or phosphodiesterase-5 inhibitors for pa-
tients in NYHA/WHO functional classes II and III and
parenteral prostanoids for patients in class IV. Several
RCTs have shown benefit when a second drug is added
to the background of a single drug (23,92–95), but others
have not (96). It is not known whether the benefits seen
in some of these trials would have been seen had the first
drug been withdrawn at the time the second drug was
added. Because most agents do not have a progression
claim, it might not be unethical to withdraw them,
although there are some safety concerns. However, the
FDA feels that there should not be a problem in a
placebo-controlled setting where an investigator can
withdraw a patient who is not doing well.
nduction therapy. Pulmonary vascular disease is very
ggressive, and late therapy might be disadvantageous. Data
how that patients randomized to placebo groups never
eally catch up: delaying therapy even 12 to 16 weeks might
e injurious (97,98). Possible strategies might involve earlier
reatment with parenteral prostanoids for patients in most
YHA/WHO classes, simultaneous initiation of 2 or more
ral drugs or an oral drug in combination with an inhaled or
subcutaneous drug, simultaneous IV prostanoid therapy
nd 1 or more nonparenteral PAH drugs, or simultaneous
se of 1 PAH drug from each category of pathologic targets.
bjections to such strategies concern the potential for drug
nteractions or toxicity, the costs of PAH drugs, the need for
nd points other than the 6MW test (99), and the current
ack of evidence-based information on drug combinations.
ecommendations. Various approaches to combination
AH therapy need to be explored in detail in well-designed
CTs. Head-to-head trials in which 2 drugs would be used
oth separately and in combination would be highly appro-
riate in the PAH population and would respond to many
f the aforementioned objections. However, it will not be
asy to garner industry support for such trials, because of the
arge numbers of patients required.
daptive design. Standard monitoring procedures for
CTs specify a primary end point and a test statistic to be
sed for the primary analysis before the initiation of the
rial. The false positive error rate for the null hypothesis and ahe statistical power to detect the targeted size of treatment
ffect are also pre-specified. Adaptive monitoring proce-
ures were developed in an attempt to streamline drug
evelopment without compromising safety. In contrast to
tandard procedures, adaptive procedures attempt to allow
odification of pre-specified design features in the course of
trial, on the basis of early efficacy and safety findings. For
xample, at an interim analysis, if the effects of the drug
eing tested are modest and it seems that the effect size
equired for statistical significance will not be achieved,
ome adaptive procedures have been proposed to enable
hanging the sample size.
The primary goal of clinical research is to obtain a timely
nd reliable evaluation of the benefit-to-risk profile of an
xperimental intervention in order to provide benefit to
ublic health (100). With that as a guiding precept, one
ight post the following objections to the use of these
daptive designs:
One must be very cautious about using approaches that
propose to allow development of hypotheses in the same
data set used to confirm them.
If additional patients are enrolled as the result of modest
effects seen at interim analysis, the second stage of the
trial would be “artificially” down-weighted, leading to a
less efficient clinical trial and making interpretability
more difficult.
Early results are often quite unreliable. Hence, use of
interim efficacy and safety data to redesign the trial might
lead to making very inappropriate changes.
Interim results regarding effects on efficacy or safety
measures should be available only to the Data Monitor-
ing Committee, to preserve the integrity and credibility
of the trial. Adaptive measures that allow redesign of the
trial on the basis of interim efficacy or safety data might
put the integrity and the credibility of the trial at risk.
This breach also reduces the flexibility to use results from
external sources that emerge during the trial to alter key
design features.
If the sponsor considers early results to be sufficiently
informative or reliable to warrant design changes, would
there be an ethical obligation to provide patients access to
this information as well?
The use of the adaptive designs overemphasizes the
importance of statistical significance relative to the im-
portance of clinical significance. It is not adequate to rely
on statistics to define a clinically significant effect.
Finally, standard monitoring procedures already provide
substantial flexibility to adapt to unexpected findings,
while maintaining the integrity and credibility of the
trial.
onclusions
t the same time that the number of pharmacologic agents
ith potential for benefit in PAH continues to grow, newnd improved modalities for measuring outcomes in RCTs
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End Points and Clinical Trial Design in PAH June 30, 2009:S97–107ontinue to emerge. Randomized controlled trials must now
e designed that will yield robust and reliable data on the
afety and efficacy of these new treatment options. The
dentification of appropriate end points for these trials is an
ntegral part of that process. Some measure of exercise
esting, time to clinical worsening, hemodynamic markers,
nd quality-of-life assessment will be among those end
oints. However, although experts can and must make
ecommendations, ultimately, agreement on optimal end
oints for RCTs in PAH will involve collaboration between
linicians, investigators, regulatory authorities, and industry.
In the short term, new therapies will undoubtedly con-
inue to extend our patients’ lives and improve their quality
f life. Our long-term goal—to reverse remodeling and
chieve a cure for this devastating disease— has not
hanged. We continue to improve our understanding of the
isease and to find better ways of treating it, and although
ur long-term goal is not yet within reach, we have reason
o believe that the likelihood of its achievement is substan-
ially increased.
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